199 related articles for article (PubMed ID: 12056699)
1. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.
Kremer LC; van Dalen EC; Offringa M; Voûte PA
Ann Oncol; 2002 Apr; 13(4):503-12. PubMed ID: 12056699
[TBL] [Abstract][Full Text] [Related]
2. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
Kremer LC; van Dalen EC; Offringa M; Ottenkamp J; Voûte PA
J Clin Oncol; 2001 Jan; 19(1):191-6. PubMed ID: 11134212
[TBL] [Abstract][Full Text] [Related]
4. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
Kremer LC; van der Pal HJ; Offringa M; van Dalen EC; Voûte PA
Ann Oncol; 2002 Jun; 13(6):819-29. PubMed ID: 12123328
[TBL] [Abstract][Full Text] [Related]
5. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
8. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline cardiotoxicity and its prevention.
Mott MG
Ann N Y Acad Sci; 1997 Sep; 824():221-8. PubMed ID: 9382447
[No Abstract] [Full Text] [Related]
11. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines.
van Dalen EC; van der Pal HJ; van den Bos C; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Oct; 42(15):2549-53. PubMed ID: 16919450
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
13. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity after liposomal anthracyclines.
Young AM; Dhillon T; Bower M
Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
[No Abstract] [Full Text] [Related]
15. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
17. A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Martoni A; Giovannini M; Tomasi L; Camaggi CM; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
Cancer Chemother Pharmacol; 1984; 12(3):179-82. PubMed ID: 6584236
[TBL] [Abstract][Full Text] [Related]
18. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
19. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
Green DM; Grigoriev YA; Nan B; Takashima JR; Norkool PA; D'Angio GJ; Breslow NE
J Clin Oncol; 2001 Apr; 19(7):1926-34. PubMed ID: 11283124
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
